DDInter1840 DDInter649
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Musculoskeletal pain {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilutamide
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Musculoskeletal pain {u} (Side Effect) is caused by {v} (Compound) Eplerenone
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Trabectedin {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) interacts with {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Enzalutamide
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Trabectedin {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Musculoskeletal pain {u} (Side Effect) is caused by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Trabectedin (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound) and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilutamide (Compound) and Nilutamide (Compound) resembles Enzalutamide (Compound)
Trabectedin (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Eplerenone (Compound) and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Trabectedin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Nilutamide (Compound) and Nilutamide (Compound) resembles Enzalutamide (Compound)
Trabectedin (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) interacts with AR (Gene) and AR (Gene) is bound by Enzalutamide (Compound)
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Trabectedin (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide